Cargando…

Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study

BACKGROUND: Few studies have systematically addressed the role of epidural analgesia and caesarean delivery in predicting the post-partum disease activity in women with Multiple Sclerosis (MS). The objective of this study was to assess the impact of epidural analgesia (EA) and caesarean delivery (CD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pastò, Luisa, Portaccio, Emilio, Ghezzi, Angelo, Hakiki, Bahia, Giannini, Marta, Razzolini, Lorenzo, Piscolla, Elisa, De Giglio, Laura, Pozzilli, Carlo, Paolicelli, Damiano, Trojano, Maria, Marrosu, Maria Giovanna, Patti, Francesco, La Mantia, Loredana, Mancardi, Gian Luigi, Solaro, Claudio, Totaro, Rocco, Tola, Maria Rosaria, Di Tommaso, Valeria, Lugaresi, Alessandra, Moiola, Lucia, Martinelli, Vittorio, Comi, Giancarlo, Amato, Maria Pia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544735/ https://www.ncbi.nlm.nih.gov/pubmed/23276328 http://dx.doi.org/10.1186/1471-2377-12-165

Ejemplares similares

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
por: Giannini, Marta, et al.
Publicado: (2012)

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
por: Pecori, Chiara, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients
por: Niccolai, Claudia, et al.
Publicado: (2015)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies
por: Bellinvia, Angelo, et al.
Publicado: (2022)

The Italian multiple sclerosis register
por: Trojano, Maria, et al.
Publicado: (2018)

The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population
por: Goretti, Benedetta, et al.
Publicado: (2014)

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
por: Iaffaldano, Pietro, et al.
Publicado: (2012)

Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis
por: Fonderico, Mattia, et al.
Publicado: (2021)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
por: Parisi, Mosè, et al.
Publicado: (2020)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis
por: Rossi, Francesca, et al.
Publicado: (2012)

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
por: Iaffaldano, Pietro, et al.
Publicado: (2022)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability
por: Giorgio, Antonio, et al.
Publicado: (2017)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics
por: Signorile, Anna, et al.
Publicado: (2020)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
por: Centonze, Diego, et al.
Publicado: (2021)

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study
por: D’Amico, Emanuele, et al.
Publicado: (2016)

Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2011)

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis
por: Portaccio, Emilio, et al.
Publicado: (2021)

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
por: Lazzaro, Carlo, et al.
Publicado: (2022)

PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels
por: De Rasmo, Domenico, et al.
Publicado: (2020)

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
por: Iaffaldano, Pietro, et al.
Publicado: (2021)

Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort
por: Manni, Alessia, et al.
Publicado: (2019)

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
por: Patti, Francesco, et al.
Publicado: (2013)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus
por: Filippi, Massimo, et al.
Publicado: (2021)

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
por: Sormani, Maria P., et al.
Publicado: (2021)

Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study
por: Bastianello, Stefano, et al.
Publicado: (2011)

Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients
por: Zoccolella, Stefano, et al.
Publicado: (2012)

Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort
por: Manni, Alessia, et al.
Publicado: (2017)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy
por: Ruggieri, Maddalena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cp8qh1d71h1kqb3e1rofl7meb0